This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar

This study has been completed.
Ministry of Science and Technology
Information provided by:
Bharat Serums and Vaccines Limited Identifier:
First received: April 6, 2009
Last updated: June 1, 2011
Last verified: June 2011
The purpose of this study is to determine whether a single bolus of dose of Amphoterin B lipid emulsion (Amphomul) is as efficacious and safe compared to a single dose Liposomal Amphotericin B in treating patients with Indian Visceral Leishmaniasis (Kala Azar).

Condition Intervention Phase
Leishmaniasis, Visceral Drug: Amphotericin B Lipid emulsion Drug: Liposomal Amphotericin B Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar)

Resource links provided by NLM:

Further study details as provided by Bharat Serums and Vaccines Limited:

Primary Outcome Measures:
  • Clinical and parasitological cure at end of treatment and final cure (no relapse) at six months [ Time Frame: Six months after dose administration ]

Secondary Outcome Measures:
  • To assess the Number of AEs, SAEs, Incidence of IRTs, with no Incidence of nephrotoxicity and hepatotoxicity and no change in the Laboratory values for different parameters [ Time Frame: within 30 to 45 days from drug administration and continue throughout duration of study ]

Enrollment: 500
Study Start Date: July 2009
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Amphotericin B lipid emulsion
Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A Drug: Amphotericin B lipid emulsion
Drug: Amphotericin B Lipid emulsion
Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
Other Name: Amphomul
Active Comparator: Liposomal Amphotericin B
Liposomal Amphotericin B in visceral leishmaniasis - 15mg/kg on day 1 in Group B
Drug: Liposomal Amphotericin B
Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
Other Name: AmBisome

Detailed Description:

Visceral Leishmaniasis, which is progressive and fatal if not treated, is an insidious, chronic disease that is characterized by irregular fever, anorexia, weight loss, cough, gross enlargement of the spleen and liver, mild anemia and emaciation. This may be preceded by rigors and vomiting. If untreated, Kala-azar, which is the most severe form of Leishmaniasis, has a mortality rate of nearly 100%.

The goal of the project is to establish that a single dose of AMPHOMUL® can be used to achieve a Definitive cure for Visceral Leishmaniasis leading to a short course therapy. The project will also seek to establish that AMPHOMUL ® is safe, at least as effective and more affordable than current treatment, and is without the risk of drug resistance.

The trial is a Prospective, Multicentric, Randomized, Two Arm, Open label Phase III study to Assess Efficacy and Safety of Infusion of Amphomul® (Amphotericin B Emulsion) as Compared to Liposomal Amphotericin B in Patients of Visceral Leishmaniasis (Kala azar)who are either treatment naive or treatment resistant to other antileishmanial drugs.


Ages Eligible for Study:   5 Years to 65 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients aged between 5 to 65 years (both inclusive).
  • Clinical signs and symptoms of Visceral Leishmaniasis (fever of over 2 weeks duration and splenomegaly)
  • Presence of amastigotes (Leishmania-Donovani bodies) at prescreening detected by rK39 dipstick test with confirmation by splenic or bone marrow aspirate smear examination.
  • Non-pregnant, non-lactating females of age ≥5 years, and woman of childbearing potential who are willing to use acceptable methods of contraception
  • Negative Urine pregnancy test (UPT) in all women

Exclusion Criteria:

  • Patients with past history of treatment with Amphotericin B or any other drug for Visceral Leishmaniasis within 30 days prior to screening.
  • Patients positive for HIV, HCV and HBsAg infection, immunocompromised patients (through history).
  • Concurrent diabetes, tuberculosis or bacterial pneumonia or any other infectious or major psychiatric disease.
  • Pregnant or nursing women
  • Patients receiving any of the medications prohibited by the study protocol.
  • Simultaneous participation in another trial or received any IP <30 days prior to enrolment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00876824

Muzaffarpur, Bihar, India, 842001
Muzaffarpur, Bihar, India, 842003
Patna, Bihar, India, 800001
Patna, Bihar, India, 800007
Sponsors and Collaborators
Bharat Serums and Vaccines Limited
Ministry of Science and Technology
Principal Investigator: Dr. Gautam Daftary, MBBS Bharat Serums and Vaccines Ltd
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Dr. Gautam V. Daftary, Bharat Serums and Vaccines Ltd Identifier: NCT00876824     History of Changes
Other Study ID Numbers: BSV-AMBE III-KA-0908
Study First Received: April 6, 2009
Last Updated: June 1, 2011

Keywords provided by Bharat Serums and Vaccines Limited:
Black Fever
Amphotericin B lipid emulsion
Liposomal Amphotericin B

Additional relevant MeSH terms:
Leishmaniasis, Visceral
Euglenozoa Infections
Protozoan Infections
Parasitic Diseases
Skin Diseases, Parasitic
Skin Diseases, Infectious
Skin Diseases
Amphotericin B
Liposomal amphotericin B
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Anti-Bacterial Agents
Antifungal Agents processed this record on August 23, 2017